## HANDBOOK OF CLINICAL NEUROLOGY

Series Editors:
MICHAEL J. AMINOFF, FRANÇOIS BOLLER,
DICK F. SWAAB

106

3rd Series

# NEUROBIOLOGY OF PSYCHIATRIC DISORDERS

Edited by:
THOMAS E. SCHLAEPFER
CHARLES B. NEMEROFF

## NEUROBIOLOGY OF PSYCHIATRIC DISORDERS

Series Editors


MICHAEL J. AMINOFF, FRANÇOIS BOLLER, AND DICK F. SWAAB


Volume Editors

THOMAS E. SCHLAEPFER AND CHARLES B. NEMEROFF

**VOLUME 106** 

3rd Series





#### ELSEVIER B.V

Radarweg 29, 1043 NX, Amsterdam, The Netherlands

© 2012 Elsevier B.V. All rights reserved.

No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval system, without permission in writing from the publisher. Permissions may be sought directly from Elsevier's Rights Department: phone: (+1) 215 239 3804 (US) or (+44) 1865 843830 (UK); fax: (+44) 1865 853333; e-mail: healthpermissions@elsevier.com. You may also complete your request on-line via the Elsevier website at http://www.elsevier.com/permissions.

This book and the individual contributions contained in it are protected under copyright by the Publisher (other than as may be noted herein).

ISBN: 9780444520029

#### **British Library Cataloguing in Publication Data**

A catalogue record for this book is available from the British Library

#### Library of Congress Cataloging in Publication Data

A catalog record for this book is available from the Library of Congress

#### Notice

Knowledge and best practice in this field are constantly changing. As new research and experience broaden our understanding, changes in research methods, professional practices, or medical treatment may become necessary.

Practitioners and researchers must always rely on their own experience and knowledge in evaluating and using any information, methods, compounds, or experiments described herein. In using such information or methods they should be mindful of their own safety and the safety of others, including parties for whom they have a professional responsibility.

With respect to any drug or pharmaceutical products identified, readers are advised to check the most current information provided (i) on procedures featured or (ii) by the manufacturer of each product to be administered, to verify the recommended dose or formula, the method and duration of administration, and contraindications. It is the responsibility of practitioners, relying on their own experience and knowledge of their patients, to make diagnoses, to determine dosages and the best treatment for each individual patient, and to take all appropriate safety precautions.

To the fullest extent of the law, neither the Publisher nor the contributors or editors, assume any liability for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein.

The Publisher

### Working together to grow libraries in developing countries

www.elsevier.com | www.bookaid.org | www.sabre.org

**ELSEVIER** 

BOOK AID International

Sabre Foundation



vour source for books. iournals and multimedia in the health sciences

www.elsevierhealth.com

Printed in China

Commissioning Editor: Michael Houston Development Editor: Michael Parkinson

Project Manager: Annie Victor Designer: Kirsteen Wright

The Publisher's policy is to use paper manufactured from sustainable forests

## NEUROBIOLOGY OF PSYCHIATRIC DISORDERS

## HANDBOOK OF CLINICAL NEUROLOGY

Series Editors

MICHAEL J. AMINOFF, FRANÇOIS BOLLER, AND DICK F. SWAAB

VOLUME 106



EDINBURGH LONDON NEW YORK OXFORD PHILADELPHIA ST LOUIS SYDNEY TORONTO 2012

#### Handbook of Clinical Neurology 3rd Series

#### Available titles

- Vol. 79, The human hypothalamus: basic and clinical aspects, Part I, D.F. Swaab ISBN 9780444513571
- Vol. 80, The human hypothalamus: basic and clinical aspects, Part II, D.F. Swaab ISBN 9780444514905
- Vol. 81, Pain, F. Cervero and T.S. Jensen, eds. ISBN 9780444519016
- Vol. 82, Motor neurone disorders and related diseases, A.A. Eisen and P.J. Shaw, eds. ISBN 9780444518941
- Vol. 83, Parkinson's disease and related disorders, Part I, W.C. Koller and E. Melamed, eds. ISBN 9780444519009
- Vol. 84, Parkinson's disease and related disorders, Part II, W.C. Koller and E. Melamed, eds. ISBN 9780444528933
- Vol. 85, HIV/AIDS and the nervous system, P. Portegies and J. Berger, eds. ISBN 9780444520104
- Vol. 86, Myopathies, F.L. Mastaglia and D. Hilton Jones, eds. ISBN 9780444518996
- Vol. 87, Malformations of the nervous system, H.B. Sarnat and P. Curatolo, eds. ISBN 9780444518965
- Vol. 88, Neuropsychology and behavioural neurology, G. Goldenberg and B.C. Miller, eds. ISBN 9780444518972
- Vol. 89, Dementias, C. Duyckaerts and I. Litvan, eds. ISBN 9780444518989
- Vol. 90, Disorders of consciousness, G.B. Young and E.F.M. Wijdicks, eds. ISBN 9780444518958
- Vol. 91, Neuromuscular junction disorders, A.G. Engel, ed. ISBN 9780444520081
- Vol. 92, Stroke Part I: Basic and epidemiological aspects, M. Fisher, ed. ISBN 9780444520036
- Vol. 93, Stroke Part II: Clinical manifestations and pathogenesis, M. Fisher, ed. ISBN 9780444520043
- Vol. 94, Stroke Part III: Investigations and management, M. Fisher, ed. ISBN 9780444520050
- Vol. 95, History of neurology, S. Finger, F. Boller and K.L. Tyler, eds. ISBN 9780444520081
- Vol. 96, Bacterial infections of the central nervous system, K.L. Roos and A.R. Tunkel, eds. ISBN 9780444520159
- Vol. 97, Headache, G. Nappi and M.A. Moskowitz, eds. ISBN 9780444521392
- Vol. 98, Sleep disorders, Part I, P. Montagna and S. Chokroverty, eds. ISBN 9780444520067
- Vol. 99, Sleep disorders, Part II, P. Montagna and S. Chokroverty, eds. ISBN 9780444520074
- Vol. 100, Hyperkinetic movement disorders, W.J. Weiner and E. Tolosa, eds. ISBN 9780444520142
- Vol. 101, Muscular dystrophies, A. Amato and R.C. Griggs, eds. ISBN 978 0 080 450315
- Vol. 102, Neuro-ophthalmology, C. Kennard and R.J. Leigh, eds. ISBN 9780444529039
- Vol. 103, Ataxic disorders, S.H. Subramony and A. Durr, eds. ISBN 9780444518927
- Vol. 104, Neuro-oncology, Part I, W. Grisold and R. Sofietti, eds. ISBN 9780444521385
- Vol. 105, Neuro-oncology, Part II, W. Grisold and R. Sofietti, eds. ISBN 9780444535023

#### Foreword

We are pleased to present, for the first time, a volume in the *Handbook of Clinical Neurology* series devoted exclusively to psychiatric disorders. It is true that Volumes 45 and 46 of the second series – on Clinical Neuropsychology and Neurobehavioral Disorders – had a few chapters that dealt with aspects of the major psychiatric disorders, but these were limited in scope and number. The volumes were published in 1985, when there was still a strict separation and even animosity between the fields of neurology and psychiatry. George W. Bruyn, one of the founders of the HCN series, however, was not convinced of any fundamental difference between these two disciplines and stated boldly that, "psychiatry is nothing but unexplained neurology."

Many neurologists of the late nineteenth and early twentieth century felt quite at home with psychiatry, which was then considered to be a special branch of neurology, a point of view shared by such luminaries as Charcot, Meynert, Von Monakow, Edinger, Wernicke, Spielmeyer, Pick, and Von Gudden. In those days, most mental hospitals had a laboratory for anatomy and pathology. Many of the famous university professors held chairs in both neurology and psychiatry, as they were interested in both the clinical and the fundamental aspects of the central nervous system. For a long time formalized residency training included both psychiatry and neurology, and the term "neuropsychiatry" was coined, to illustrate the integration of the two fields.

Psychotherapy, developed by Sigmund Freud in the early 1900s, was the principal method of treatment for mental disorders throughout the 1950s. The emergence of analytical psychiatry gradually led to a schism between neurology and psychiatry. For instance, in the Netherlands this resulted in a complete separation between the two when, in 1974, the Dutch Society for Neurology and Psychiatry was split into two separate societies.

In the meantime, in the late 1950s, the first antipsychotic and antidepressant drugs came into widespread use and their clinical effects resulted in "chemical imbalance" hypotheses of mental disorders. This formed the conceptual basis for the development of "biological psychiatry": research now focused on the brain itself and on the neurobiological mechanisms that caused disorders such as depression and schizophrenia. We have thus, in a sense, come full circle to a situation where the differences and borders between psychiatry and neurology are once again blurred. Mental illnesses are now considered to be genetically and environmentally influenced disorders of brain chemistry. The emergence and development of imaging techniques have contributed tremendously to the shift of attention to the neurosciences in psychiatry. The structural and molecular basis of neuropsychiatric disorders is becoming clearer, making the present volume an extremely timely one.

We congratulate the two volume editors, Thomas Schlaepfer and Charles Nemeroff, for putting together this outstanding volume, which will appeal to psychiatrists, neurologists and neuroscientists alike. Clinical, genetic, molecular, imaging, neuropathological, immunological, epidemiological, metabolic, therapeutic and historical aspects of the major psychiatric disorders are reviewed in a thoughtful and scholarly manner. In addition, the potential and limitations of animal experimental models for these disorders are extensively discussed.

As always we are very grateful to the team at Elsevier, and especially to Mr. Michael Parkinson, for expert assistance in the development and production of this volume.

Michael J. Aminoff François Boller Dick F. Swaab

#### **Preface**

"I don't consider this my science. This is my avocation. But that avocation has been completely influenced by my science."

Eric Kandel in a 1996 lecture commemorating the 100th anniversary of the New York State Psychiatric Institute, Columbia University College of Physicians and Surgeons.

This volume on psychiatric disorders appears for the first time in the prestigious *Handbook of Clinical Neurology* series; an event that affirms our belief of a fundamental conceptual shift in the conceptualization of mental disorders. Psychiatry is the medical discipline diagnostically assessing and treating patients with multifaceted and complex brain disorders that represent the leading causes of disability worldwide. These disorders are highly prevalent; each year over 25% of adult Americans carry the diagnosis of at least one mental disorder and similar data has been reported for Europe. The public health impact of depression is in part due to the fact that available treatments are suboptimal; in the case of major depression, up to 40% of patients responding to antidepressant therapy suffer from clinically relevant residual symptoms despite optimized treatment and a large sequenced treatment (STAR\*D) study, which analyzed outcome following several standardized treatment steps, reported that 33% of patients did not respond despite four evidence-based treatment steps. Historically, brain disorders of unknown etiology fell in the domain of psychiatry and those with known etiology in the domain of neurology.

The quotation above by Eric Kandel was published in 1998. This paper and several others by him and others that predate it had a significant influence on the science of psychiatry, by addressing the conceptual shift from a purely psychoanalytic framework, often conceptualized as the antithesis of biological psychiatry, to the synthesis of psychiatry as a truly comprehensive, behavioral neuroscience. By studying the sea slug Aplysia and the fruit fly Drosophila, Kandel and his colleagues demonstrated that memory storage depends on the coordinated expression of specific genes that code for proteins that alter structural elements of the brain. This is particularly notable because Kandel, born in Vienna, connected after his immigration to the USA to that city's psychiatric history by training as a psychoanalyst, a profession at that time far removed from the biological sciences. When Sigmund Freud – the founder of psychoanalysis – explored implications of unconscious mental processes for behavior, he tried to adopt a neuroscientific model of behavior in an attempt to develop a scientific psychology. He proposed that the cognitive mechanisms of normal and abnormal mental phenomena could be explained through orderly and rigorous study of brain systems. Given the state of scientific methodology in psychiatry at the time – mainly restricted to histopathology and assessing brain states by verbal reports of patient's subjective experiences – this was a somewhat futile attempt.

During the 20th century, a series of rapidly changing emphases have been prominent within psychiatry, each one dominating a period spanning two or more decades. These developments have contributed to both diffusion and confusion about what psychiatry really is and what it stands for, ultimately affecting the credibility of the profession. The long-standing tradition of moving disorders from the domain of psychiatry to neurology once the pathophysiology was elucidated, as occurred with pellagra and neurosyphilis, has now finally ended with understanding that the major psychiatric disorders are in fact brain diseases. Research on brain disorders has led to novel insights into etiology and pathogenesis using brain imaging techniques and molecular methods. Thus a number of genetic risk factors for psychiatric and neurological disorders have been identified and molecular pathological mechanisms are increasingly being scrutinized in appropriate experimental models. Molecular research has even lead to recognition of the biological consequences and transgenerational impacts of violence and abuse. The application of the rapidly increasing knowledge base in molecular and cellular neurobiology into psychiatry presages a new understanding of psychiatric illness and its treatment, thereby overcoming the ideological struggles between

X PREFACE

biology and psychodynamics—a confrontation that often was detrimental to patient care. The application of evidence-based medicine to psychotherapeutic treatments has revealed the efficacy of cognitive behavior therapy (CBT), interpersonal psychotherapy (IPT), dialectical behavior therapy (DBT) and most notably in some recent studies, psychodynamic psychotherapy. Molecular biological research has lead to new hypotheses on brain disorders; this research will undoubtedly lead to conceptually new therapeutic strategies and the understanding of the mechanisms of action of effective psychopharmacological and psychotherapeutic treatments. In the future it will be germane to strengthen translational research approaches, a process in which new basic research findings will be translated to clinical application — and from bench to bedside and back — clinical observations are fed back to basic research allowing the generation of new testable hypotheses.

In this volume we sought to provide a comprehensive and integrated view of psychiatric care and its current scientific foundations in 45 chapters. To give a truly international overview – well within the tradition of Sigmund Freud and Eric Kandel – we invited two authors for each chapter, recognized experts in the chapter's subject area, one from the USA and one from elsewhere. In most cases this ambitious goal was achieved, resulting in outstanding reviews of the topics reflecting the international state of the science. Each chapter was reviewed by the editors and the series editors to assure completeness of coverage and quality. We truly believe that the burgeoning body of research on the pathogenesis and pathophysiology of psychiatric illness and the increasing number of treatments available to patients reviewed in this volume is at last beginning to lift the stigma of mental illness and offering hope to those who suffer from it.

Thomas E. Schlaepfer Charles B. Nemeroff

#### Contributors

#### J.L. Ayuso-Mateos

Psychiatry Department, Hospital Universitario de la Princesa, Universidad Autónoma de Madrid, Madrid, Spain

#### A.-M. Bao

Department of Neurobiology, Institute of Neuroscience, Zhejiang University School of Medicine, Hangzhou, China, and Netherlands Institute for Neuroscience, an institute of the Royal Netherlands Academy of Arts and Sciences, Amsterdam, The Netherlands

#### M.F. Beal

Department of Neurology and Neuroscience, Weill Medical College of Cornell University, New York, NY, USA

#### M. Berger

Department of Psychiatry and Psychotherapy, University Medical Center Freiburg, Freiburg, Germany

#### G.E. Berrios

Neuropsychiatry Service, University of Cambridge, Cambridge, UK

#### R.M. Bilder

Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, and Department of Psychology, UCLA College of Letters & Science, and UCLA Semel Institute for Neuroscience and Human Behavior, Los Angeles, CA, USA

#### E.B. Binder

Department of Psychiatry and Behavioral Sciences and Department of Genetics, Emory University Atlanta, GA, USA, and Max Planck Institute of Psychiatry, Munich, Germany

#### J. Blanch

Psychiatry Department, Institute of Neurosciences, Hospital Clínic de Barcelona, Barcelona, Spain

#### R.M. Bonelli

Department of Neuropsychiatry, Sigmund Freud University Vienna, Vienna, Austria

#### O. Boxer

Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, and Department of Psychology, UCLA College of Letters & Science, and UCLA Semel Institute for Neuroscience and Human Behavior, Los Angeles, CA, USA

#### S. Brunnhuber

Department of Psychiatry and Psychotherapy II, SALK, University of Salzburg, Salzburg, Austria

#### L.M. Cancela

Department of Pharmacology, University of Cordoba, Cordoba, Argentina

#### A. Ciaramella

Department of Oncology, Azienda Ospedaliera University of Pisa, Pisa, Italy

#### S. Claes

Department of Psychiatry, University Psychiatric Center, Campus Leuven, University of Leuven, Leuven, Belgium

#### L. Clark

Department of Experimental Psychology, MRC–Wellcome Trust Behavioural and Clinical Neurosciences Institute, University of Cambridge, Cambridge, UK

#### M. Cristancho

Clinical Research Scholars Program, Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, PA, USA

#### J.F. Cubells

Department of Human Genetics and Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA, USA

#### K.V. Danilenko

Institute of Internal Medicine, Siberian Branch of the Russian Academy of Medical Sciences, Novosibirsk, Russia

#### D. Denys

Department of Psychiatry, Academic Medical Centre, Amsterdam, The Netherlands

#### M. Deuschle

Central Institute of Mental Health, Mannheim, Germany

#### **B.W.** Dunlop

Mood and Anxiety Disorders Program, Emory University School of Medicine, Atlanta, GA, USA

#### T.D. Ely

Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA, USA

#### E.J. Engstrom

Department of History, Humboldt University, Berlin, Germany

#### C. Fassbender

Department of Psychiatry and Behavioral Sciences, MIND Institute, University of California Davis School of Medicine, Sacramento, CA, USA

#### P. Fossati

Department of Psychiatry, Salpêtrière Hospital, Paris, France

#### G. Gabbard

Menninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, TX, USA

#### S.-F. Gao

Department of Neurobiology, Institute of Neuroscience, Zhejiang University School of Medicine, Hangzhou, China

#### M. Gerardi

Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA, USA

#### M. Gerlach

Laboratory of Clinical Neurochemistry, Department of Child and Adolescent Psychiatry and Psychotherapy, University of Würzburg, Würzburg, Germany

#### S.N. Ghaemi

Department of Psychiatry, Tufts Medical Center, Boston, MA, USA

#### S. Gibiino

Institute of Psychiatry, University of Bologna, Bologna, Italy

#### C.F. Gillespie

Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA, USA

#### J.M. Gorman

Comprehensive Neuroscience Inc, White Plains, NY, USA

#### L. Gray

Clinical Research Scholars Program, Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, PA, USA

#### B. Greenberg

Department of Psychiatry and Human Behavior, Brown University, Butler Hospital, Providence, RI, USA

#### C. Guilleminault

Stanford University Sleep Disorders Program, Stanford, CA, USA

#### P.D. Harvey

Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA, USA

#### U. Hegerl

Department of Psychiatry, University of Leipzig, Leipzig, Germany

#### C.M. Heim

Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA, USA

#### S.P. Henderson Powell

Spring Grove Hospital Center, Catonsville, MD, USA

#### B. Herpertz-Dahlmann

Department of Child and Adolescent Psychiatry, RWTH Aachen University, Aachen, Germany

#### R.B. Hidalgo

Department of Psychiatry, Depression and Anxiety Disorders Research Institute, University of South Florida College of Medicine, Tampa, FL, USA

#### K. Holtkamp

DRK Clinic of Child and Adolescent Psychiatry, Bad Neuenahr, Germany

此为试读,需要完整PDF请访问: www.ertongbook.com

#### P. Holtzheimer

Department of Psychiatry and Behavioral Sciences, Emory University, Atlanta, GA, USA

#### L.J. Hoppe

ACSENT Laboratory, Department of Psychology and Department of Psychiatry, University of Cape Town, Medical Research Council of South Africa – Anxiety and Stress Disorders Unit, Cape Town, South Africa

#### N.S. Hudepohl

Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, OH, USA

#### J. Ipser

Department of Psychiatry, University of Cape Town, Groote Schuur Hospital, Cape Town, South Africa

#### M.R. Irwin

Cousins Center for Psychoneuroimmunology, Semel Institute for Neuroscience, University of California, Los Angeles CA, USA

#### E.G. Iskander

Mount Sinai Medical Center, New York, NY, USA

#### S.H. Juul

Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA, USA

#### P.W. Kalivas

Department of Neurosciences, Medical University of South Carolina, Charleston, SC, USA

#### C. Kilts

Brain Imaging Research Center, Psychiatric Research Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA

#### K. Konrad

Neuropsychology Section, Department of Child and Adolescent Psychiatry, RWTH Aachen University, Aachen, Germany

#### G.F. Koob

Committee on the Neurobiology of Addictive Disorders, The Scripps Research Institute, La Jolla, CA, USA

#### M. Kosel

Department of Psychiatry, University of Bonn, Bonn, Germany

#### K.R.R. Krishnan

Department of Psychiatry and Behavioural Sciences, Duke University Medical Center, Durham, NC, USA

#### R.A. Lanius

Department of Psychiatry, University of Western Ontario, London, Ontario, Canada

#### Y. Lecrubier

French National Institute of Health and Medical Research (INSERM), Paris, France; now deceased

#### R.D. Levitan

Department of Psychiatry, Centre for Addiction and Mental Health, University of Toronto, Toronto, Canada

#### A.R. Lingford-Hughes

Department of Neuropsychopharmacology, Imperial College, London, UK

#### L. Lit

Department of Psychiatry and Behavioral Sciences and Department of Neurology, MIND Institute, University of California Davis School of Medicine, Sacramento, CA, USA

#### D. Maust

Clinical Research Scholars Program, Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, PA, USA

#### E.A. Mayer

Center for Neurobiology of Stress, Division of Digestive Diseases, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA

#### W. McDonald

Department of Psychiatry and Behavioral Sciences, Emory University, Atlanta, GA, USA

#### J. McPartland

Department of Psychiatry, Yale Child Study Center, New Haven, CT, USA

#### R. Mergl

Department of Psychiatry, University of Leipzig, Leipzig, Germany

#### T. Müller

Department of Neurology, St. Josef Hospital, Ruhr University Bochum, Bochum, Germany

#### J. Muñoz-Moreno

Fundació Lluita Contra la SIDA, Hospital Universitari Germans Trias i Pujol, Badalona, Spain

#### **CONTRIBUTORS**

#### H.A. Nasrallah

Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, OH, USA

#### U.M. Nater

Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA, USA

#### C.B. Nemeroff

Department of Psychiatry and Behavioral Sciences, Leonard M. Miller School of Medicine University of Miami, Miami, FL, USA

#### D.J. Nutt

Neuropsychopharmacology Unit, Centre for Pharmacology and Therapeutics, Division of Experimental Medicine, Department of Medicine, Imperial College, London, UK

#### P. Olgiati

Institute of Psychiatry, University of Bologna, Bologna, Italy

#### C.M. Pariante

Institute of Psychiatry, King's College London, London, UK

#### C.R. Raison

Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA, USA

#### M.M. Rasenick

Departments of Physiology & Biophysics and Psychiatry, University of Illinois Chicago College of Medicine, Chicago, IL, USA, and Jesse Brown VA Medical Center, Chicago, IL

#### G. Reeves

Department of Psychiatry, Division of Child and Adolescent Psychiatry, University of Maryland School of Medicine, Baltimore, MD, USA

#### A.G. Reid

Oxford Health NHS Foundation Trust, Specialist Community Addiction Service-Bucks (SCAS-B), High Wycombe, UK

#### P. Riederer

Department of Psychiatry and Psychotherapy and NPF Center of Excellence Laboratories, University of Würzburg, Würzburg, Germany

#### K.J. Ressler

Department of Psychiatry and Behavioral Sciences and Yerkes Research Center, Emory University, Atlanta, GA, USA

#### R. Reverte

Psychiatry Department, Fundació Pere Mata de les Terres de l'Ebre, Amposta, Spain

#### R.G. Robinson

Department of Psychiatry, Roy J and Lucille A Carver College of Medicine, The University of Iowa, Iowa City, IA, USA

#### S. Roose

Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York, NY, USA

#### B. Rothbaum

Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA, USA

#### M. Rothermundt

Department of Psychiatry, University of Muenster, Muenster, Germany

#### H.G. Ruhé

Program for Mood Disorders AMC/De Meren, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands

#### S. Rushing

Clinical Research Scholars Program, Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, PA, USA

#### **B.J. Sahakian**

Department of Psychiatry, University of Cambridge School of Clinical Medicine, Addenbrooke's Hospital, Cambridge, UK

#### S.E. Sarkstein

School of Psychiatry and Clinical Neurosciences, University of Western Australia, Perth, Australia

#### T. Schlaepfer

Department of Psychiatry, University of Bonn, Germany, and Division of Psychiatric Neuroimaging, Department of Psychiatry, The Johns Hopkins Hospital, Baltimore, MD, USA

#### C. Schmahl

Department of Psychosomatic Medicine and Psychotherapy, Central Institute of Mental Health, Mannheim, Germany

#### E. Schramm

Department of Psychiatry and Psychotherapy, University Medical Center Freiburg, Freiburg, Germany

#### J.B. Schweitzer

Department of Psychiatry and Behavioral Sciences, MIND Institute, University of California Davis School of Medicine, Sacramento, CA, USA

#### A. Serretti

Institute of Psychiatry, University of Bologna, Bologna, Italy

#### D.V. Sheehan

Depression and Anxiety Disorders Research Institute, University of South Florida College of Medicine, Tampa, FL, USA

#### L.I. Sinclair

Academic Unit of Psychiatry, Bristol University, Bristol, UK

#### L.J. Siever

Department of Psychiatry, Bronx VA Medical Center, New York, NY, USA

#### D.J. Smith

Department of Psychological Medicine, Cardiff University, Cardiff, UK

#### G. Spalletta

Department of Clinical and Behavioral Neurology, IRCCS Santa Lucia Foundation and Department of Neuroscience, Tor Vergata University of Rome, Rome, Italy

#### D. Spiegel

Department of Psychiatry & Behavioral Sciences and Center for Integrative Medicine, Stanford University School of Medicine, Stanford, CA, USA

#### D.J. Stein

Department of Psychiatry, University of Cape Town, Groote Schuur Hospital, Cape Town, South Africa

#### D.F. Swaab

Netherlands Institute for Neuroscience, Amsterdam, The Netherlands

#### Y.-L. Tang

Department of Human Genetics, Emory University School of Medicine, Atlanta, GA, USA

#### M. Terman

College of Physicians and Surgeons, Columbia University, New York State Psychiatric Institute and Center for Environmental Therapeutics, New York, NY, USA

#### M.E. Thase

Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, PA, USA

#### C. Tjoa

Clinical Research Scholars Program, Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, PA, USA

#### D. Tranel

Departments of Neurology and Psychology, Division of Behavioral Neurology and Cognitive Neuroscience, University of Iowa College of Medicine, Iowa City, IA, USA

#### E. Vermetten

Department of Psychiatry, University Medical Center; Rudolf Magnus Institute of Neurosciences, Utrecht, The Netherlands

#### U. Voderholzer

Department of Psychiatry and Psychotherapy, University of Freiburg Medical Center, Freiburg, Germany

#### F.R. Volkmar

Yale Child Study Center, New Haven, CT, USA

#### M.M. Weber

Historical Archive, Max Planck Institute of Psychiatry, Munich, Germany

#### E.A. Whitham

Department of Psychiatry, Tufts Medical Center, Boston, MA, USA

#### A. Wirz-Justice

Centre for Chronobiology, Psychiatric University Clinics, Basel, Switzerland

#### **CONTRIBUTORS**

#### M.B.H. Youdim

Faculty of Medicine, Technion-Rappaport Family, and Eve Topf and US National Parkinson Foundation, Centers of Excellence for Neurodegenerative Diseases Research and Teaching, Haifa, Israel

#### J.-Z. Yu

Departments of Physiology & Biophysics and Psychiatry, University of Illinois Chicago College of Medicine, Chicago, IL, USA, Department of Pathology and Laboratory Medicine, U. Rochester Medical School, Rochester NY

#### J. Zohar

Department of Psychiatry, Chaim Sheba Medical Center, Tel Hashomer, Israel

### Contents

Foreword vii Preface ix Contributors xi

1.	M.M. Weber, G.E. Berrios, and E.J. Engstrom (Munich, Germany, Cambridge, UK, and Berlin, Germany)	1
2.	Receptor signaling and the cell biology of synaptic transmission JZ. Yu and M.M. Rasenick (Chicago, IL, USA)	9
3.	Human genetics of schizophrenia S. Claes, YL. Tang, C.F. Gillespie, and J.F. Cubells (Leuven, Belgium and Atlanta, GA, USA)	37
4.	Neurological and psychiatric aspects of emotion S.E. Starkstein and D. Tranel (Perth, Australia and Iowa City, IA, USA)	53
5.	Research methods: cognitive neuropsychological methods  L. Clark, O. Boxer, B.J. Sahakian, and R.M. Bilder (Cambridge, UK and Los Angeles, CA, USA)	75
6.	Structural imaging in psychiatric disorders K.R.R. Krishnan (Durham, NC, USA)	89
7.	Human functional neuroimaging C. Kilts and T.D. Ely (Little Rock, AR and Atlanta, GA, USA)	97
8.	Neurotransmitters and neuropeptides in depression AM. Bao, H.G. Ruhé, SF. Gao, and D.F. Swaab (Hangzhou, China and Amsterdam, The Netherlands)	107
9.	Animal models of psychiatric disorders G.F. Koob (La Jolla, CA, USA)	137
10.	Psychiatric epidemiology S.H. Juul and C.B. Nemeroff (Atlanta, GA and Miami, FL, USA)	167
11.	Emerging methods in the molecular biology of neuropsychiatric disorders E.B. Binder and K.J. Ressler (Atlanta, GA, USA and Munich, Germany)	191
12.	Clinical psychoneuroimmunology M.R. Irwin and M. Rothermundt (Los Angeles, CA, USA and Muenster, Germany)	211
13.	Psychiatric rating scales  D. Maust, M. Cristancho, L. Gray, S. Rushing, C. Tjoa, and M.E. Thase (Philadelphia, PA, USA)	227

xviii CONTENTS

14.	Unipolar depression C.M. Pariante and C.B. Nemeroff (London, UK and Miami, FL, USA)	239
15.	<b>Bipolar disorder</b> D.J. Smith, E.A. Whitham, and S.N. Ghaemi (Cardiff, UK and Boston, MA, USA)	251
16.	The neurobiology and treatment of late-life depression U. Hegerl, P. Holtzheimer, R. Mergl, and W. McDonald (Leipzig, Germany and Atlanta, GA, USA)	265
17.	Seasonal affective disorder K.V. Danilenko and R.D. Levitan (Novosibirsk, Russia and Toronto, Ontario, Canada)	279
18.	Biological and clinical framework for posttraumatic stress disorder E. Vermetten and R.A. Lanius (Utrecht, The Netherlands and London, Ontario, Canada)	291
19.	Generalized anxiety disorder  R.B. Hidalgo and D.V. Sheehan (Tampa, FL, USA)	343
20.	Panic disorder L.J. Hoppe, J. Ipser, J.M. Gorman, and D.J. Stein (Cape Town, South Africa and White Plains, NY, USA)	363
21.	Obsessive-compulsive disorder  J. Zohar, B. Greenberg, and D. Denys (Tel Hashomer, Israel, Providence, RI, USA, and Amsterdam, The Netherlands)	375
22.	Attention-deficit/hyperactivity disorder  J.B. Schweitzer, C. Fassbender, L. Lit, G. Reeves, and S.P. Henderson Powell (Sacramento, CA, Baltimore, MD, and Catonsville, MD, USA)	391
23.	Autism and related disorders  J. McPartland and F.R. Volkmar (New Haven, CT, USA)	407
24.	Substance abuse disorders A.G. Reid, A.R. Lingford-Hughes, L. Cancela, and P.W. Kalivas (London, UK, Cordoba, Argentina, and Charleston, SC, USA)	419
25.	Cognitive impairment in schizophrenia: profile, course, and neurobiological determinants $P.D.\ Harvey\ (Miami,\ FL,\ USA)$	433
26.	Eating disorders: anorexia and bulimia nervosa B. Herpertz-Dahlmann, K. Holtkamp, and K. Konrad (Aachen and Bad Neuenahr, Germany)	447
27.	Personality disorders G.O. Gabbard, C. Schmahl, L.J. Siever, and E.G. Iskander (Houston, TX, USA, Mannheim, Germany, and New York, NY, USA)	463
28.	Psychiatric, nonmotor aspects of Parkinson's disease T. Müller, M. Gerlach, M.B.H. Youdim, and P. Riederer (Bochum and Würzburg, Germany, and Haifa, Israel)	477
29.	Stroke R.G. Robinson and G. Spalletta (Iowa City, IA, USA and Rome, Italy)	49]